logo
Menu

We provide briefings on technologies to different public stakeholders, from those delivering care and research funders stimulating innovation, to policy makers and advisory bodies. Most, if not all of these briefings, will be publicly available on this website via the search window.

Innovation Observatory > Reports > Drugs > Udenafil for congenital heart disease in adolescents after fontan palliation

< Back

Udenafil for congenital heart disease in adolescents after fontan palliation

Drugs

Cardiovascular Disease and Vascular Surgery

October 2018


Udenafil as an oral tablet is in clinical development for congenital heart disease in adolescents after Fontan palliation. Functional single ventricle congenital heart disease is a condition in which babies are born with one of their lower heart chambers (ventricles) not working. As a result, the heart cannot pump blood properly to the lungs and the rest of the body. The Fontan operation is the final of three surgeries in the strategy of staged palliation for children born with congenital heart defects resulting in functional single-ventricle physiology. Fontan patients may have a shortened life span, often not surviving past the third or fourth decade of life, due to many factors including deteriorating ventricular performance and increasing pulmonary vascular resistance.

Udenafil works by blocking the enzyme phosphodiesterase type 5 which regulates the breakdown of ‘cyclic guanine monophosphate’ (cGMP) in the blood vessels of the lungs. Increased levels of cGMP leads to dilation (widening) of the vessels improving blood flow to the lungs, reducing the burden on the heart and improving oxygen supply to the blood. This is expected to improve the symptoms of the condition and may offer an additional treatment option for adolescents (12-18 years old) for the management of congenital heart disease after Fontan palliation who currently have few effective therapies available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts